만성 신장병 치료제 시장 : 약제 클래스별, 투여 경로별, 적응증별, 유통 채널별, 지역별
Chronic Kidney Disease Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography
상품코드
:
1672647
리서치사
:
Coherent Market Insights
발행일
:
2025년 02월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 만성 신장병 치료제 시장은 2025년에 159억 2,000만 달러로 추정되며, 2032년에는 230억 2,000만 달러에 달할 것으로 예측되며, 2025-2032년에 CAGR 5.4%로 성장할 것으로 예측됩니다.
| 보고 범위 |
보고서 상세 내용 |
| 기준연도 |
2024년 |
2025년 시장 규모 |
159억 2,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간: 2025-2032년 CAGR: |
5.40% |
2032년 가치 예측 |
230억 2,000만 달러 |
도표. 2025년 지역별 만성신장질환 치료제 시장 점유율(%)
세계 만성 신장질환 치료제 시장의 성장을 주도하는 것은 전 세계 신장질환 유병률 증가입니다. 만성콩팥병(CKD)은 시간이 지남에 따라 신장 기능이 점차적으로 저하되는 것을 말하며, CKD를 치료하지 않고 방치하면 결국 신부전이나 말기 신장질환으로 이어질 수 있으며, CKD의 일반적인 원인으로는 당뇨병, 고혈압, 사구체신염, 다낭성 신염, 다낭성 신질환 등이 있습니다. 노인 인구 증가와 생활습관병 증가는 CKD의 유병률 증가로 이어질 수 있습니다. 만성콩팥병 치료제는 질병의 진행을 늦추고, 합병증을 치료하며, 신장 전체의 건강을 유지하는 것을 목표로 합니다. 레닌-안지오텐신계 억제제, 칼슘 채널 차단제, 적혈구 조혈 촉진제, 이뇨제 등이 만성콩팥병 관리에 사용되는 주요 약제군입니다.
시장 역학:
세계 만성 신장질환 치료제 시장의 성장을 주도하는 것은 당뇨병과 고혈압의 유병률 증가입니다. 국제당뇨병연맹이 발표한 자료에 따르면 2021년에는 전 세계에서 약 5억 3,700만 명의 성인이 당뇨병을 앓고 있습니다. 이 수치는 2030년에는 6억 4,300만 명, 2045년에는 7억 8,300만 명으로 증가할 것으로 예측됩니다. 고혈압도 CKD의 주요 원인입니다. 신장질환의 조기 진단과 치료에 대한 인식을 높이기 위한 정부의 적극적인 노력이 시장 성장을 가속할 수 있습니다. 그러나 신약 승인에 대한 엄격한 규제와 장기 치료에 따른 심각한 부작용의 위험은 시장 성장을 저해할 수 있습니다. 병용요법 및 표적치료제 개발은 만성신장질환 치료제 제조업체에게 유리한 기회를 제공합니다.
본 조사의 주요 특징
세계의 만성신장질환 치료제 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR%)을 게재하고 있습니다.
또한 다양한 부문에 걸친 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
세계 만성신장질환 치료제 시장의 주요 기업을 기업 개요, 제품 포트폴리오, 주요 특징, 실적, 전략 등의 매개변수를 기반으로 프로파일링합니다.
본 조사의 대상이 되는 주요 기업은 Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.가 있습니다.
이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
세계 만성 신장질환 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 만성신장질환 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장의 전망
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER의 산업 분석
- 합병과 인수 시나리오
제4장 세계의 만성 신장병 치료제 시장, 약제 클래스별, 2020-2032년(10억 달러)
- ACE 저해제
- 안지오텐신 수용체 길항제(ARB)
- B 블로커
- 칼슘 채널 차단약
- 루프 이뇨제
- 적혈구 조혈 자극제(ESA)
- 인산 결합제
- 기타
제5장 세계의 만성 신장병 치료제 시장, 투여 경로별, 2020-2032년(10억 달러)
제6장 세계의 만성 신장병 치료제 시장, 적응증별, 2020-2032년(10억 달러)
- 당뇨병성 신장질환
- 사구체신염
- 고혈압성 신증
- 다낭성 신장 질환
- 기타 적응증
제7장 세계의 만성 신장병 치료제 시장, 유통 채널별, 2020-2032년(10억 달러)
제8장 세계의 만성 신장병 치료제 시장, 지역별, 2020-2032년, (10억 달러)
- 북미
- 라틴아메리카
- 유럽
- 아시아태평양
- 중동
- 아프리카
제9장 경쟁 구도
- AstraZeneca
- Amgen Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Sanofi
- GlaxoSmithKline plc(GSK)
- AbbVie Inc.
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Akebia Therapeutics, Inc.
제10장 애널리스트의 권장사항
- 운명의 수레바퀴
- 애널리스트의 견해
- COM(Coherent Opportunity Map)
제11장 참고 문헌과 조사 방법
KSA
영문 목차
Global Chronic Kidney Disease Drugs Market is estimated to be valued at USD 15.92 Bn in 2025 and is expected to reach USD 23.02 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 15.92 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
5.40% |
2032 Value Projection: |
USD 23.02 Bn |
Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2025
Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.
Market Dynamics:
Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.
Key features of the study:
This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market
Detailed Segmentation-
- By Drug Class
- ACE Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- B-Blockers
- Calcium Channel Blockers
- Loop Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Others
- By Route of Administration:
- By Indication
- Diabetic Nephropathy
- Glomerulonephritis
- Hypertensive Nephropathy
- Polycystic Kidney Disease
- Other Indications
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Key Players Insights
- AstraZeneca
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Sanofi
- GlaxoSmithKline plc (GSK)
- AbbVie Inc.
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Akebia Therapeutics, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Chronic Kidney Disease Drugs Market, By Drug Class
- Global Chronic Kidney Disease Drugs Market, By Route of Administration
- Global Chronic Kidney Disease Drugs Market, By Indication
- Global Chronic Kidney Disease Drugs Market, By Distribution Channel
- Global Chronic Kidney Disease Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Angiotensin Receptor Blockers (ARBs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- B-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Loop Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Erythropoiesis-Stimulating Agents (ESAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phosphate Binders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parentral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Chronic Kidney Disease Drugs Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Diabetic Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Glomerulonephritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hypertensive Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Polycystic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Chronic Kidney Disease Drugs Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, V (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- GlaxoSmithKline plc (GSK)
- AbbVie Inc.
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Akebia Therapeutics, Inc.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
관련자료
